

# HISTAMINE H<sub>2</sub>-ANTAGONIST

Navneet F. Chauhan, Ph.D Associate Professor, Saraswati Institute of Pharmaceutical Sciences, Gandhinagar


#### HISTAMINE H<sub>2</sub>-ANTAGONISTS

- Drugs whose pharmacological action primarily involves antagonism of the action of histamine at its H<sub>2</sub>-receptors.
- Therapeutic application in the treatment of acid-peptic disorders including heartburn, gastroesophageal reflux disease (GERD), erosive esophagitis, gastric and duodenal ulcers, and gastric acid pathologic hypersecretory diseases such as Zollinger-Ellison syndrome.
- They are also useful in combination with  $H_1$ -antihistamines for the treatment of chronic urticaria and for the itching of anaphylaxis and pruritis.
- Classification of H<sub>2</sub>-Antagonist
  - a) Imidazole ring analogue (Cimetidine)
  - b) Furan ring analogue (Ranitidine)
  - c) Thiazole ring analogue (Famotidine & Nizatidine)

## SAR of H<sub>2</sub>-Antagonist

37 tit of 112 7 titagoriist	
Histamine: Nonselective histamine receptor agonist (H <sub>1</sub> = H <sub>2</sub> )	H <sub>2</sub> C—CH <sub>2</sub> NH <sub>2</sub>
5-Methylhistamine: Selective $H_{2}$ -agonist ( $H_{2} > H_{1}$ )	H NH2
	H <sub>2</sub> C — CH <sub>2</sub>
N°-Guanylhistamine: Partial H <sub>2</sub> -receptor agonist (weak antagonist)	H <sub>2</sub> C—CH <sub>2</sub> NH <sub>2</sub>
Burimamide: Full H <sub>2</sub> -receptor antagonist; but low potency and poor oral bioavailability	H <sub>2</sub> C—CH <sub>2</sub> s
	H NHCH <sub>3</sub>
Metiamide: Full H <sub>2</sub> -receptor antagonist with higher potency and improved oral bioavailability; but toxicity resulting from the thiourea	H <sub>2</sub> C — CH <sub>2</sub> S N— C NHCH <sub>3</sub>
Cimetidine: Full H <sub>2</sub> -receptor antagonist with higher potency and improved oral bioavailability and low systemic toxicity	$H_3C$ $H_2C$ $S$ $CH_2-CH_2$ $N$

## Hormonal Regulation of Acid Secretion by Parietal Cell



### Synthesis of Cimetidine

4-(2-aminomethyl)-thiomethyl-5-methylimidazol

thiourea derivative

#### **IUPAC Name:**

1-cyano-2-methyl-3-[2-[[5-[[methylimidazol-4-yl)methyl]thio]ethyl] guanidine

### Structures of H<sub>2</sub>-Receptor Antagonist

$$C = N$$
 $C = N$ 
 $C$ 

Cimetidine exhibits relatively good bioavailability (60% - 70%)
Side Effect: Cimetidine has a weak antiandrogenic effect, and it may cause gynecomastia in patients treated for 1 month or more.

$$H_2N$$
 $N \longrightarrow SO_2NH_2$ 
 $N \longrightarrow NH_2$ 
 $N \longrightarrow SO_2NH_2$ 
 $N \longrightarrow SO_2NH_2$ 
 $N \longrightarrow SO_2NH_2$ 
 $N \longrightarrow SO_2NH_2$ 

Famotidine is a competitive inhibitor of histamine  $H_2$ -receptors with a potency significantly greater than cimetidine.

Nizatidine has excellent oral bioavailability (90%). Nizatidine is more potent than Cimetidine

#### **IUPAC Name:**

N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thiol]ethyl]-N-methyl-2-nitro-1,1 ethenediamine

Ranitidine is more potent than cimetidine, but less potent than famotidine. Like other H<sub>2</sub>-antagonists, it does not appear to bind to other receptors.